News & Views
Major US Cancer Centre places New System Order
Oct 23 2020 Read 438 Times
Medical-imaging technology company Polarean which offers an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, has received its latest research unit order for a 9820 Xenon Polariser system from the University of Texas MD Anderson Cancer Center, a major cancer research and teaching hospital.
The new unit will initiate their research programme using hyperpolarised noble gas imaging in oncology, including assessing lung function as consequence of chemotherapy and radiation therapies and providing guidance for improved radiation treatment planning, among other topics.
Richard Hullihen, CEO of Polarean, said: "We are excited to begin our relationship with MD Anderson Cancer Center who have pioneered such a breadth of oncology applications for medical imaging for this patient population, and welcome them to the group of our users researching the use of hyperpolarised 129 Xe in pulmonary function.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - The Movement Towards More Comprehensive Testing of Mycotoxins in Cannabis - Addressing proper HACCP implementation - Micropatterning: The art of micro-controlling...
View all digital editions
Dec 08 2020 Beijing, China
Dec 08 2020 VIrtual event
Dec 09 2020 Tokyo, Japan
Dec 09 2020 Virtual event
Dec 13 2020 Virtual event